Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares OutstandingShares OutstandingShares Repurchased
Ratios

Core Laboratories (CLB) Shares Outstanding (2022 - 2025)

Core Laboratories' Shares Outstanding history spans 4 years, with the latest figure at $47.0 million for Q4 2025.

  • For Q4 2025, Shares Outstanding changed 0.3% year-over-year to $47.0 million; the TTM value through Dec 2025 reached $47.0 million, changed 0.3%, while the annual FY2025 figure was $47.0 million, 0.3% changed from the prior year.
  • Shares Outstanding reached $46.1 million in Q4 2025 per CLB's latest filing, roughly flat from $46.1 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $47.0 million in Q1 2025 to a low of -$109594.0 in Q3 2022.
  • Average Shares Outstanding over 4 years is $43.6 million, with a median of $46.7 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding: grew 0.76% in 2023, then decreased 0.24% in 2024.
  • A 4-year view of Shares Outstanding shows it stood at $46.6 million in 2022, then rose by 0.66% to $46.9 million in 2023, then fell by 0.24% to $46.8 million in 2024, then grew by 0.3% to $47.0 million in 2025.
  • Per Business Quant, the three most recent readings for CLB's Shares Outstanding are $47.0 million (Q4 2025), $47.0 million (Q3 2025), and $47.0 million (Q2 2025).